Survodutide: Research Overview

Survodutide (BI 456906) is an investigational once-weekly subcutaneous glucagon receptor and GLP-1 receptor dual agonist in late-stage clinical development. It was discovered by Zealand Pharma and licensed to Boehringer Ingelheim, which is solely responsible for development and commercialisation. Survodutide is not approved by the FDA, EMA, or any regulatory agency as of May 2026. Phase 3 trials in obesity and a phase 3 cardiovascular outcomes trial are ongoing, and the compound received FDA Breakthrough Therapy Designation for metabolic dysfunction-associated steatohepatitis (MASH) based on compelling phase 2 data.

What is Survodutide?

Survodutide is a synthetic peptide analogue designed as a balanced co-agonist of the glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R). Zealand Pharma licensed it to Boehringer Ingelheim under a partnership in which Zealand receives milestone payments and royalties while Boehringer leads all clinical and commercial activities. The compound is administered once weekly by subcutaneous injection and is being evaluated in three primary disease settings: obesity without type 2 diabetes (SYNCHRONIZE-1), obesity with type 2 diabetes (SYNCHRONIZE-2), and MASH with liver fibrosis (LIVERAGE program).

In April 2026, Boehringer Ingelheim announced top-line phase 3 results from the SYNCHRONIZE-1 trial showing 16.6% mean body weight loss with survodutide versus placebo in adults with obesity. This was the first phase 3 weight-loss readout for survodutide. The compound also has a cardiovascular outcomes trial (SYNCHRONIZE-CVOT) ongoing.

Mechanism of Action

Like mazdutide, survodutide achieves its pharmacological effects through simultaneous agonism of two GPCRs. GLP-1 receptor activation on pancreatic beta cells drives glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and enhances central satiety signalling. These effects produce glycaemic control and appetite suppression.

Glucagon receptor agonism adds a distinct and complementary dimension: hepatic fatty acid oxidation is upregulated, thermogenesis is enhanced, and lipolysis in adipose tissue is stimulated. In the liver, GCGR activation is hypothesised to reduce lipid accumulation and promote steatosis resolution, which is the rationale for survodutide's development in MASH. The combined receptor engagement may allow greater weight loss and hepatic benefit than GLP-1 agonism alone, though the clinical validation of this mechanistic hypothesis is the purpose of ongoing trials.

What the Research Shows

The phase 2 obesity dose-finding trial (le Roux CW et al., Lancet Diabetes Endocrinol. 2024;12:162–173; PMID 38330987) randomised 387 adults with overweight or obesity to survodutide (0.6 mg, 2.4 mg, 3.6 mg, or 4.8 mg) or placebo once weekly for 46 weeks. Weight loss was dose-dependent: mean changes of −6.2%, −12.5%, −13.2%, and −14.9% at the respective doses versus −2.8% with placebo. All active doses were tolerated, and adverse events were predominantly gastrointestinal and mild to moderate. These results supported progression to the phase 3 SYNCHRONIZE program.

The SYNCHRONIZE-1 trial is a multinational, randomised, double-blind, placebo-controlled phase 3 trial in people with obesity without type 2 diabetes (PubMed PMID 41187967 for baseline characteristics publication). Top-line results announced by Boehringer Ingelheim in April 2026 showed a mean body weight reduction of 16.6% with survodutide versus placebo, with meaningful improvements in cardiometabolic markers. Full results are pending publication.

SYNCHRONIZE-2 is the companion phase 3 trial in people with obesity and type 2 diabetes (baseline characteristics: Wharton et al., Diabetes Obes Metab. 2026). Results from SYNCHRONIZE-2 were not yet reported as of May 2026.

The phase 2 MASH trial (randomised, double-blind, placebo-controlled, 48 weeks; 295 participants with biopsy-confirmed MASH and fibrosis stages F1–F3) was presented at EASL 2024 and published simultaneously in the New England Journal of Medicine (PMID 38847460). Survodutide demonstrated striking results: improvement in MASH without worsening of fibrosis occurred in 47%, 62%, and 43% of participants in the 2.4 mg, 4.8 mg, and 6.0 mg groups, respectively, versus 14% in the placebo group. Fibrosis improvement (one stage or more) was achieved in up to 52.3% of treated participants versus 25.8% with placebo. In the F2/F3 subgroup, up to 64.5% of survodutide-treated patients achieved fibrosis improvement without worsening of MASH versus 25.9% with placebo.

These MASH results, particularly the fibrosis improvement signal, supported the FDA Breakthrough Therapy Designation for survodutide in MASH and the initiation of the LIVERAGE phase 3 MASH program. MASH is an area of high unmet medical need and significant regulatory interest.

Pharmacokinetics

Survodutide supports once-weekly subcutaneous dosing, indicating a half-life in the range of several days. Phase 2 dose-finding data confirmed adequate exposure across the 0.6–4.8 mg dose range with dose-proportional pharmacokinetics. Phase 3 doses (the exact approved dose range pending regulatory review) are based on the phase 2 tolerability and efficacy profile. Clearance is primarily proteolytic. Detailed phase 3 PK data have not been fully published in peer-reviewed literature as of May 2026; prescribing information at time of potential approval will be the authoritative source.

Common Research Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

In the published phase 2 obesity trial, doses ranged from 0.6 mg to 4.8 mg once weekly. The MASH phase 2 trial used doses of 2.4 mg, 4.8 mg, and 6.0 mg once weekly. Phase 3 SYNCHRONIZE trials used doses up to approximately 4.8 mg once weekly, escalated per protocol. Survodutide is not approved and does not have a defined therapeutic dose outside clinical trials.

Storage and Handling

As an investigational compound, survodutide is not commercially available, and there is no approved product label. Clinical trial formulations of peptide injectables are generally stored refrigerated at 2–8°C (36–46°F) and protected from freezing and light, consistent with GLP-1 class compounds. Storage conditions for any future approved formulation will be specified in the prescribing information at the time of regulatory approval.

What It Is NOT

Survodutide is not mazdutide (IBI362), which is the Innovent/Lilly GLP-1/GCGR dual agonist approved in China. The two compounds are structurally distinct peptides developed by different companies, despite sharing the same receptor mechanism. Survodutide is not tirzepatide, which targets GLP-1R and GIPR. It is not retatrutide, which is a triple agonist. Survodutide is not semaglutide or any currently approved GLP-1 receptor agonist. It has no regulatory approval as of May 2026 and is not available outside of clinical trials. It is not a GHRH peptide and has no relationship to the CJC-1295 or tesamorelin compound class.

References

Key citations include the phase 2 obesity trial (le Roux et al., Lancet Diabetes Endocrinol 2024, PMID 38330987), the phase 2 MASH trial (NEJM 2024, PMID 38847460), the SYNCHRONIZE-1 baseline characteristics publication (PMID 41187967), and Boehringer Ingelheim press releases for the April 2026 SYNCHRONIZE-1 phase 3 top-line readout.